Page 18 of 83
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

18

nanotimes

Companies Facts

b

itop AG, Germany, which specializes in the development and marketing of Ectoin®

-

containing medical devices, announces that Ectoin® significantly reduces nanoparticle-induced in- flammatory reaction in rat lungs, one of the animal models for chronic obstructive pulmonary disease (COPD). It is the first time that Ectoin®

has been

shown to have such an effect on nanoparticle-indu- ced lung inflammation. Current therapy for COPD is treatment with glucocorticoids that, however, have only limited effect on nanoparticle-induced lung

inflammation even when inhaled. Carbon nanopar- ticles (CNPs), a well-accepted model for the carbo- naceous core of combustion-derived nanoparticles, induce lung inflammation in rats by causing an influx of neutrophil granulocytes into the lung epithelium. Ectoin®

, given locally with or before the application

of nanoparticles, reduced neutophil influx by about 30%. Furthermore, it prevented CNP-induced incre- ase in cinc-1 release. http://www.bitop.de

10-05/06 :: May/June 2010

Advertisement

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83